The European Medicines Agency (EMA) recommends the marketing of AstraZeneca’s Evusheld preventive treatment for people over 12 years of age. This medicine is intended for people who lack antibodies and whose body is resistant to vaccination.
The European regulator’ has recommended granting marketing authorization for Evusheld, developed by AstraZeneca AB, for the prevention of Covid-19 in adults and adolescents from 12 years of age weighing at least 40 kg before exposure potential’ to the virus, he said in a statement Thursday.
Evusheld combines two types of synthetic antibodies (tixagevimab and cilgavimab). It is administered as two intramuscular injections. It is considered effective once morest the Omicron variant.
These antibodies help the immune system fight off the virus if it is encountered, by targeting its Spike protein, which allows it to enter cells to infect them.
The European regulator said it made this decision following analyzing the results of a study of more than 5,000 people. “Evusheld’s safety profile was favorable and side effects were generally mild, with a small number of people experiencing reactions,” the EMA said.
The regulator concluded that the drug’s benefits outweigh its risks in approved use. He will now send his recommendation to the European Commission for a quick decision applicable in all EU member states.
/ ATS
